Results for “screening”

Detect horizontal gene transfer (HGT / LGT) using compositional methods (GC%, codon usage, tetranucleotide z-scores via SIGI-HMM, AlienHunter, IslandViewer 4, IslandPath-DIMOB), phylogenetic-incongruence methods (AvP, HGTphyloDetect, ALE / GeneRax / AleRax reconciliation, RANGER-DTL), and BLAST-distribution methods (HGTector v2, DarkHorse, Alien Index). Use when screening prokaryote genomes for genomic islands and HGT events, distinguishing HGT from incomplete lineage sorting / differential gene loss / hybridization, mapping donor lineages via phylogenetic placement, separating eukaryotic HGT from contamination, ruling out gBGC as a false signal, or quantifying DTL rates with ALE/GeneRax on bacterial trees.

The English summary is being prepared. Showing the original description.

Calls HLA class I and class II alleles at 2/4/6/8-field resolution from WGS/WES/RNA-seq/long-read data using OptiType, HLA-LA, T1K, Polysolver, HLA-HD, arcasHLA, StarPhase, or HIBAG imputation. Use when typing for HSCT, solid-organ transplant, neoantigen prediction, PGx screening (B*57:01, B*15:02, etc.), or disease-association studies, with reconciliation across tools and IPD-IMGT/HLA version mismatch handling.

The English summary is being prepared. Showing the original description.

Performs retrosynthetic planning using AiZynthFinder (MCTS, template-based), Chemformer (template-free transformer), ASKCOS, and emerging RetroSynFormer with explicit handling of route scoring, building-block availability (eMolecules, Enamine, Mcule), forward prediction validation (Molecular Transformer), and disconnection-aware multi-objective search (MO-MCTS). Use when assessing synthetic feasibility of generated or selected molecules, planning multi-step syntheses, building synthesis-aware design pipelines, or screening libraries for retro-route feasibility.

The English summary is being prepared. Showing the original description.

Decompose total effects into direct and indirect paths through mediators using mediation, CMAverse 4-way, HIMA/HIMA2 high-dimensional, BAMA, two-step / MVMR mediation, or double-ML medDML. Use when testing whether a molecular phenotype (expression, methylation, protein) mediates a treatment-outcome relationship, decomposing exposure-mediator interaction via VanderWeele 4-way, screening high-dimensional EWAS mediators, or running MR-based mediation when sequential ignorability is implausible.

The English summary is being prepared. Showing the original description.

Calculates molecular fingerprints (ECFP/Morgan, FCFP, MACCS, RDKit, AtomPair, TopologicalTorsion, Avalon, MAP4, MHFP6) and physicochemical descriptors (Lipinski, QED, TPSA, Crippen LogP, 3D shape) with explicit choice tables, bit vs count semantics, and partial-charge model selection. Use when featurizing molecules for similarity, QSAR, virtual screening, or ML, or selecting the correct fingerprint for a chemotype-aware task.

The English summary is being prepared. Showing the original description.

Builds and applies 3D pharmacophore models using RDKit Pharm3D, the apo2ph4 receptor-based workflow (Heider et al 2022/2023 J Chem Inf Model 63:147-158), Pharmer / Pharmit (search), and PharmacoForge (diffusion-based generation, Flynn et al 2025 Front Bioinform), covering ligand-based pharmacophore (from active set alignment) and receptor-based pharmacophore (from binding pocket geometry). Explicit handling of feature types, geometric tolerances, partial matching, and pharmacophore-based virtual screening. Use when identifying scaffold-hopping candidates, building shape-and-feature search queries, or transferring SAR across chemotypes.

The English summary is being prepared. Showing the original description.

Runs cis-pQTL Mendelian randomization for drug-target validation using UKB-PPP (Olink), deCODE (SomaScan), Fenland, INTERVAL, ARIC, and FinnGen-PPP proteomes plus colocalization triangulation, phenome-wide on-target adverse-effect scans, cross-platform Olink/SomaScan replication, and PAV (protein-altering variant) sensitivity. Use when nominating or de-risking a drug target from plasma-proteome GWAS, mimicking pharmacological inhibition via cis-pQTL instruments, separating shared-causal from LD-confounded signal under the Schmidt 2020 cis-MR framework, screening on-target adverse phenotypes pheWAS-style, or producing publication-grade STROBE-MR plus PP.H4 evidence for a target gene.

The English summary is being prepared. Showing the original description.

Searches molecular libraries for substructure matches using SMARTS patterns with explicit handling of recursive SMARTS, ring membership, aromaticity dialect, vector binding, atom map indices, and reactive/PAINS/REOS/Brenk/Aldridge filter catalogs. Use when filtering compounds by pharmacophore features, functional groups, scaffold matches, or screening for assay-interference / structural alerts.

The English summary is being prepared. Showing the original description.

Estimate bivariate genetic correlation (rg) between traits from GWAS summary statistics or individual-level genotypes using cross-trait LDSC, HDL, LAVA, rho-HESS, GREML-bivariate, Popcorn, and HDL-L. Use when quantifying shared genetic architecture between two traits, screening MR validity before causal inference, distinguishing global from locus-level rg, estimating trans-ancestry rg, separating partial from full causation via LCV gcp, or producing a STROBE-MR-compliant cross-trait sensitivity battery. Cross-trait LDSC intercept absorbs sample overlap and is NOT a bias; HDL is biased under sample overlap above ~5%. High rg between exposure and outcome motivates CHP-aware MR sensitivity (CAUSE, LHC-MR).

The English summary is being prepared. Showing the original description.

Assesses RNA-seq data quality specifically for alternative splicing analysis. QC layers include experimental design audit (library prep, read length, depth, replicates), STAR 2-pass cohort-style alignment, junction saturation curves and discovery plateau detection, novel-vs-known junction ratio diagnostics, junction-overhang distribution, splice-site strength scoring (MaxEntScan intrinsic + SpliceAI context-aware), strandedness verification, GENCODE basic vs comprehensive choice, and rRNA contamination screening. Splicing analysis is more demanding than DGE on read length, depth, library prep, alignment strategy, and annotation choice — failures silently bias PSI estimates and inflate novel-junction false positives. Use when evaluating data suitability for splicing analysis, troubleshooting low event detection, or designing sequencing experiments where AS is a primary endpoint.

The English summary is being prepared. Showing the original description.

Use this skill when the user asks how to recruit CDL drivers — sourcing channels (CDL schools, job boards, military, returning citizens, owner-operator pools), application + screening process, signing bonus structures, recruitment marketing, fleet ambassador programs, and what's working in the current driver market. Reference ATA Workforce Development.

The English summary is being prepared. Showing the original description.

Use this skill when a driver is being screened for sleep apnea. Covers FMCSA Medical Review Board (MRB) recommendations, BMI thresholds, sleep study referrals, and continued certification.

The English summary is being prepared. Showing the original description.

Use this skill when the user asks where to find specific information at fmcsa.dot.gov — the SAFER (Safety and Fitness Electronic Records System), Carrier Snapshot, Compliance Safety Accountability (CSA) data, PSP (Pre-Employment Screening Program), Clearinghouse, Unified Carrier Registration (UCR), MCS-150 update, complaints, DataQs, and the FMCSA Portal login. Reference fmcsa.dot.gov.

The English summary is being prepared. Showing the original description.

Use this skill when the user asks how to interpret a DOT medical examiner's findings — what restrictions mean (corrective lenses, hearing aid, no insulin, etc.), what conditions trigger short-term vs 24-month certificates, vision/hearing thresholds, blood pressure categories, sleep apnea screening, when to seek an exemption program, and how to handle a downgrade or denial. Cite 49 CFR 391.41-49 and the FMCSA Medical Examiner Handbook.

The English summary is being prepared. Showing the original description.

Use this skill to evaluate whether credit reports are appropriate for driver applicant screening. Covers EEOC guidance, FCRA, and common carrier policies.

The English summary is being prepared. Showing the original description.

Codified expertise for customs documentation, tariff classification, duty optimization, restricted party screening, and regulatory compliance across multiple jurisdictions. Informed by trade compliance specialists with 15+ years experience. Includes HS classification logic, Incoterms application, FTA utilization, and penalty mitigation. Use when handling customs clearance, tariff classification, trade compliance, import/export documentation, or duty optimization.

The English summary is being prepared. Showing the original description.

World-Class Risk Management Playbook. Use for: business continuity planning (BCP), disaster recovery (DR), scenario planning, fraud prevention & detection, reputational risk management, geopolitical risk assessment, insurance & risk transfer, crisis communication, enterprise risk management (ERM), risk registers, BIA, RTO/RPO, ISO 22301, ISO 31000, COSO ERM, NIST CSF, DORA, operational resilience, three lines of defence, risk appetite, internal controls, segregation of duties, synthetic identity fraud, deepfake fraud, AML/CFT, KYC, sanctions screening, social listening, vendor risk, geopolitical exposure mapping, parametric insurance, cyber insurance, D&O, KRIs, risk dashboards. Trigger when discussing ANY risk management, business continuity, disaster recovery, fraud prevention, reputational risk, geopolitical risk, insurance strategy, crisis management, operational resilience, or enterprise risk topic. If in doubt, use this skill.

The English summary is being prepared. Showing the original description.

用财务指标快速排除垃圾股，找到有基本面支撑的标的。用于A股基本面选股。

The English summary is being prepared. Showing the original description.

Build leveraged buyout models in Excel — sources & uses, debt schedule, cash sweep, exit multiple, IRR/MOIC sensitivity. Pairs with excel-author. Use for PE screening, sponsor-case valuation, or illustrative LBO in a pitch.

The English summary is being prepared. Showing the original description.

Use when a systematic, scoping, or rapid review needs a reproducible pipeline: protocol framing (PICO/SPIDER/PCC), a logged search string, title/abstract and full-text screening with recorded exclusion reasons, and PRISMA flow counts, with the human as the deciding screener.

The English summary is being prepared. Showing the original description.

Use for the search-planning stage of a literature review, when database lanes and language layers must be chosen, when DOI coverage policy is unclear, or when inclusion and exclusion criteria need drafting before any source is read; not for running the screening and PRISMA pipeline of a formal review, which is prisma-scoping-review-pipeline.

The English summary is being prepared. Showing the original description.

Use when choosing a journal for a finished or nearly finished manuscript, when index status in Scopus, SSCI, ESCI, or TR Dizin must be confirmed, when a venue looks predatory, or when a cover letter needs drafting from the manuscript's actual claims.

The English summary is being prepared. Showing the original description.

Integrate Self (self.xyz) — a privacy-first identity protocol using zero-knowledge proofs to verify passports and ID cards. Use when the user mentions Self protocol, Self identity, self.xyz, passport verification, zero-knowledge identity verification, SelfAppBuilder, SelfBackendVerifier, SelfVerificationRoot, or wants to add privacy-preserving KYC, age verification, nationality checks, OFAC screening, or Sybil resistance using real-world identity documents. Covers frontend QR code integration, backend proof verification, and on-chain smart contract verification on Celo.

The English summary is being prepared. Showing the original description.